Skip to main content
ADTX
NASDAQ Life Sciences

Aditxt Reports Severe Financial Distress, Nasdaq Delisting Threat, and Massive Derivative Liabilities in Q1 2026

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$1.43
Mkt Cap
$46.898K
52W Low
$1.34
52W High
$53,450.606
Market data snapshot near publication time

summarizeSummary

Aditxt, Inc. reported a substantial net loss and negative equity in Q1 2026, alongside a Nasdaq delisting notice and a dramatic increase in derivative liabilities, highlighting severe financial distress and significant future dilution risks.


check_boxKey Events

  • Severe Financial Distress and Going Concern Doubt

    The company reported a net loss of $16.19 million for Q1 2026, a significant increase from $5.95 million in Q1 2025. Total stockholders' equity shifted to a deficit of $35.17 million from a positive $3.95 million, and the cash balance plummeted to $268,852 as of March 31, 2026. Management explicitly states 'substantial doubt' about its ability to continue as a going concern beyond one year.

  • Nasdaq Delisting Notice Received

    Aditxt, Inc. received a Nasdaq Staff Determination letter on May 6, 2026, notifying it of delisting for failing to meet the minimum $1.00 bid price. The company is ineligible for a compliance period due to multiple reverse stock splits over the past two years and is appealing the decision.

  • Massive Increase in Derivative Liabilities

    Derivative liabilities surged to $35.45 million as of March 31, 2026, from just $2 at December 31, 2025. This increase is primarily due to anti-dilution provisions on warrants and preferred stock conversion features becoming effective, indicating significant potential future dilution.

  • Ongoing Dilutive Capital Raising Activities

    The company sold 1,857 shares for $633,631 under its At-The-Market (ATM) program in Q1 2026 and increased the ATM capacity to $53.4 million on March 27, 2026. Additionally, from April 1 to May 19, 2026, 2,353 shares of Series A-1 Preferred Stock converted into 666,382 common shares, and 110,737 warrants were exercised for 110,737 common shares. New senior unsecured promissory notes with a principal of $1.25 million (net proceeds $1.0 million) were issued on April 10, 2026, featuring aggressive redemption terms.


auto_awesomeAnalysis

Aditxt, Inc. is in a critical financial state, facing an imminent Nasdaq delisting and reporting a significant increase in net loss and negative equity. The massive surge in derivative liabilities, primarily from anti-dilution provisions on warrants and preferred stock, signals substantial future dilution for shareholders. While the proposed sale of a recently acquired subsidiary could provide much-needed capital, the company's current cash position is extremely weak, and its ability to continue as a going concern is in serious doubt. Investors should monitor the outcome of the Nasdaq appeal and the progress of the proposed asset sale.

At the time of this filing, ADTX was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.9K. The 52-week trading range was $1.34 to $53,450.61. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ADTX - Latest Insights

ADTX
May 20, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
9
ADTX
May 15, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
May 14, 2026, 8:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ADTX
May 08, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
9
ADTX
May 08, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
May 01, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
ADTX
Apr 23, 2026, 4:30 PM EDT
Filing Type: 424B3
Importance Score:
8
ADTX
Apr 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
Apr 10, 2026, 9:49 PM EDT
Filing Type: S-3
Importance Score:
9
ADTX
Apr 07, 2026, 4:02 PM EDT
Filing Type: 8-K/A
Importance Score:
9